ENLIVEN is the first randomized, placebo-controlled phase 3 trial evaluating systemic therapy for tenosynovial giant cell tumor (TGCT). It asked whether pexidartinib, an oral CSF1 receptor inhibitor, could reduce tumor burden and improve function in patients with symptomatic, advanced TGCT not amenable to surgery. 120 patients across 12 countries were randomized to pexidartinib or placebo for 24 weeks.
TGCT is not a malignancy, but the diffuse subtype causes progressive joint destruction, repeated surgeries, and long-term disability. Before ENLIVEN, no approved systemic option existed, and surgeons were left with imatinib or nilotinib off-label at response rates of 6–19%.
Pexidartinib targets the CSF1/CSF1R axis that drives tumor cell recruitment — not the neoplastic cells themselves, but the inflammatory microenvironment that constitutes the bulk of TGCT. The 39% RECIST response and 56% TVS response at 6 months, sustained at 22-month follow-up without a median duration of response reached, represent a meaningful treatment effect in a disease with no prior standard systemic option.
The safety signal demands your attention in practice. The cholestatic hepatotoxicity seen here is mechanistically distinct from simple transaminase elevation (a known CSF1R class effect on Kupffer cells). The bilirubin-plus-alkaline-phosphatase pattern does not meet Hy's law criteria, meaning standard hepatotoxicity monitoring algorithms will not catch it. Any patient on pexidartinib needs alkaline phosphatase and bilirubin checked alongside transaminases, with heightened vigilance in the first 8 weeks.
For the trainee, the key decision framework is: pexidartinib is reserved for patients with symptomatic, advanced TGCT where surgery would worsen function or cause severe morbidity. It is not a first-line substitute for resection in operable disease.
ENLIVEN is the first randomized, placebo-controlled phase 3 trial evaluating systemic therapy for tenosynovial giant cell tumor (TGCT). It asked whether pexidartinib, an oral CSF1 receptor inhibitor, could reduce tumor burden and improve function in patients with symptomatic, advanced TGCT not amenable to surgery. 120 patients across 12 countries were randomized to pexidartinib or placebo for 24 weeks.
TGCT is not a malignancy, but the diffuse subtype causes progressive joint destruction, repeated surgeries, and long-term disability. Before ENLIVEN, no approved systemic option existed, and surgeons were left with imatinib or nilotinib off-label at response rates of 6–19%.
Pexidartinib targets the CSF1/CSF1R axis that drives tumor cell recruitment — not the neoplastic cells themselves, but the inflammatory microenvironment that constitutes the bulk of TGCT. The 39% RECIST response and 56% TVS response at 6 months, sustained at 22-month follow-up without a median duration of response reached, represent a meaningful treatment effect in a disease with no prior standard systemic option.
The safety signal demands your attention in practice. The cholestatic hepatotoxicity seen here is mechanistically distinct from simple transaminase elevation (a known CSF1R class effect on Kupffer cells). The bilirubin-plus-alkaline-phosphatase pattern does not meet Hy's law criteria, meaning standard hepatotoxicity monitoring algorithms will not catch it. Any patient on pexidartinib needs alkaline phosphatase and bilirubin checked alongside transaminases, with heightened vigilance in the first 8 weeks.
For the trainee, the key decision framework is: pexidartinib is reserved for patients with symptomatic, advanced TGCT where surgery would worsen function or cause severe morbidity. It is not a first-line substitute for resection in operable disease.